Clinical Trials

Several clinical trials evaluate interventions for conditions including stage I–IV and recurrent uterine corpus carcinoma, Lynch syndrome, midshaft clavicle fractures, major depressive and anxiety disorders, and chronic pain. Sponsored by academic, foundation, and governmental organizations, these non-interventional or early feasibility studies have reported phases categorized as unassigned or not applicable. Active enrollment is currently absent across the studies, with recruitment statuses designated as either not yet recruiting or suspended.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01199250 Not yet recruiting
Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation
 2100-01 --
NCT05454306 Suspended
Clavicle Fracture
University of Minnesota
 2028-01-09 Not Applicable
NCT05118594 Not yet recruiting
Major Depressive Disorder|Dysthymic Disorder|Specific Phobia|Social Anxiety Disorder|Panic Disorder|Agoraphobia|Generalized Anxiety Disorder
National Council of Scientific and Technical Research Argentina
 2026-02 Not Applicable
NCT06077526 Not yet recruiting
Chronic Pain
Bridgewater College
 2026-01-13 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 3'-Hydroxypterostilbene product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K and p38MAPK pathways while concurrently activating ERK1/2 and JNK1/2 MAPK cascades to block downstream pro-survival intracellular signaling. This dual pathway modulation triggers programmed cell death and autophagy, leading to suppressed cell proliferation and tumor growth inhibition relevant to clinical trial evaluations in oncology conditions such as uterine corpus carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.